aVaxziPen announces positive data for multiple diseases with novel needle-free vaccine
aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will present data at the World Vaccine Congress (WVC) in Washington, US. The company plans to present a poster stating: “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.”
The immunogenicity data from four in vivo models suggests that the company’s needle-free solid-dose vaccine platform is an efficient way to deliver vaccines for various indications, including tetanus, anthrax, inf luenza and peanut allergies. The technology not only improves ease of administration and accessibility, but also has the potential to reduce vaccine hesitancy associated with needle-phobia.
The solid-dose formulation is also intended to improve thermal stability of standard-of-care vaccines, potentially reducing the need for cold-chain logistics during vaccine distribution.
The data presented at the WVC showed immunogenicity equivalence for aVaxziPen’s needle-free solid-dose vaccines compared to traditional needle and syringe vaccines in four examples: a recombinant attenuated vaccinia virus expressing a peanut allergen, a tetanus toxoid vaccine with an alum adjuvant, a recombinant protective antigen anthrax vaccine and a recombinant inf luenza H7 vaccine.
Dr Keith Howard, aVaxziPen’s chief scientific officer, commented: “With our needle-free technology we’re on a mission to transform vaccine delivery for the benefit of communities around the world. Our novel solid-dose formulation technology coupled with our ‘click-and-deliver’ pen device has the potential to improve the accessibility and costeffectiveness of every-day vaccines. The latest in vivo data, presented in Washington at the World Vaccine Congress, demonstrates how our technology generates comparable immune responses for several vaccines in a needle-free presentation.”